A Phase I/II, Single and Repeat Dose, Dose Escalation Study of AV0328 Administered to Healthy Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs AV 0328 (Primary)
- Indications Bacterial infections; Staphylococcal infections
- Focus Adverse reactions
- Sponsors Alopexx Vaccine
- 25 Oct 2017 According to an Alopexx Vaccine media release, the phase I portion of this trial is completed.
- 15 Aug 2017 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
- 15 Aug 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Jun 2019.